Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389916 · ClinicalTrials.gov registry record · NA
Euclid Phoenix Lens Design Trial
A NA study of Myopia and Cornea, sponsored by Euclid Systems Corporation.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT06389916: Active NA study of Myopia and Cornea, sponsored by Euclid Systems Corporation.
NCT06389916 is a NA study of Myopia and Cornea that is active but no longer recruiting, run by Euclid Systems Corporation. The registered enrollment target is 30 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06389916, a NA study of Myopia and Cornea, is active but no longer recruiting, sponsored by Euclid Systems Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The "first fit" success rate of the current Euclid orthokeratology "MAX" lens design will be compared to that of the new Euclid orthokeratology MAX "Phoenix" lens design in 30 children.
Interventions
- DEVICE Euclid orthokeratology MAX (current design)
- DEVICE Euclid orthokeratology MAX Phoenix (new design)
Study Locations (5)
California
- Insight Vision Center Optometry - Costa Mesa
Florida
- Dau Family Eye Care - Saint Johns
Minnesota
- Cornea and Contact Lens Institute of Minnesota - Edina
New Jersey
- Somerset Eye Care - North Brunswick
Virginia
- Treehouse Eyes - Tysons Corner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2024-04 |
| Phase | NA |
What the registry record for NCT06389916 still lists
NCT06389916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Euclid orthokeratology MAX (current design) is the first listed.
NCT06389916 lists 5 locations in 5 states (California, Florida, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06389916 about?
NCT06389916 is a clinical study titled "Euclid Phoenix Lens Design Trial". The "first fit" success rate of the current Euclid orthokeratology "MAX" lens design will be compared to that of the new Euclid orthokeratology MAX "Phoenix" lens design in 30 children.
What is the current status of trial NCT06389916?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2024-04.
What conditions does trial NCT06389916 study?
This clinical trial studies the following conditions: Myopia, Cornea.
What interventions are being tested in trial NCT06389916?
The interventions under investigation include: Euclid orthokeratology MAX (current design) (DEVICE), Euclid orthokeratology MAX Phoenix (new design) (DEVICE).
Who is sponsoring clinical trial NCT06389916?
This trial is sponsored by Euclid Systems Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06389916 being conducted?
This trial has 5 study locations across California, Florida, Minnesota, New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06389916's enrollment target sits among peer trials
30 86th of 90 higher than 4 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI